Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.

The pharma, biotech and allied industries came back together in London on 2 December to celebrate a year of exceptional achievement at the 17th Annual Scrip Awards, hosted by the journalist and broadcaster Amol Rajan.

The biopharma market has been highly active throughout the COVID-19 pandemic with a substantial focus on strategic alliances between 2020-H1 2021. Partnership deals present exciting liquidity and risk mitigation opportunities for early-stage companies. Small molecules still comprise the largest segment of partnered drugs, but alliances for other modalities are on the rise.

The biotech sector is awash with capital and the rise of the virtual roadshow is breaking down geographic barriers, giving European firms a better chance to impress US investors.